Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non‐Muscle‐Invasive Bladder Cancer
Cancer Science · 2026-03 · 117 (3) · 787-796
DOI: 10.1111/cas.70311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.12.2025. Verfasst von Zihan Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor, DNA, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Joint Funds of the Natural Science Foundation of Tianjin, Scientific Research Project of Tianjin Municipal Education Commission.
Abstract (Originalsprache)
Repeat transurethral resection of bladder tumor (re‐TURBT) is commonly recommended for patients with non–muscle‐invasive bladder cancer (NMIBC) with high‐risk features, although many individuals may undergo unnecessary procedures that increase morbidity without clear benefit. Urinary tumor DNA (utDNA) has emerged as a promising biomarker, and we evaluated the performance of a multidimensional utDNA assay (utLIFE) in this context. In a retrospective cohort of 161 patients who underwent re‐TURBT between May 2020 and May 2025, urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which integrates shallow whole‐genome sequencing and targeted sequencing of 155 genes with machine learning–based classification. Residual tumor was identified in 35% of patients, and utLIFE demonstrated high diagnostic accuracy, with sensitivity of 80.7%, specificity of 96.2%, and overall accuracy of 90.7%, markedly outperforming urine cytology. A positive utLIFE result was the strongest independent predictor of residual disease (OR = 77.5, 95% CI: 22.4–268.2, p < 0.001). During a median follow‐up of 32.5 months, recurrence occurred in 20.5% of patients; recurrence was defined as urothelial tumor relapse within the urinary tract and did not include distant metastasis. utLIFE positivity was significantly associated with shorter recurrence‐free survival (HR = 16.4, 95% CI: 2.7–101.8, p = 0.003). Longitudinal testing further revealed that utDNA positivity frequently preceded cystoscopic evidence of recurrence by several months. These findings highlight the strong diagnostic and prognostic value of utDNA in identifying residual disease and predicting recurrence, supporting its potential role in refining postoperative management strategies for NMIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
- Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Second Hospital of Tianjin Medical University, Tianjin, China.
ORCID-Profile: Zihan Xue, Zhouliang Wu, Hailong Hu
Förderung
- National Natural Science Foundation of China
- Joint Funds of the Natural Science Foundation of Tianjin
- Scientific Research Project of Tianjin Municipal Education Commission
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Xue, Z., Qie, Y., Shen, C., Wu, Z., Chen, H., Lin, Y., Li, R., Huang, S., & Hu, H. (2026). Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non‐Muscle‐Invasive Bladder Cancer. Cancer Science, 117(3), 787-796. https://doi.org/10.1111/cas.70311
Vancouver
Xue Z, Qie Y, Shen C, Wu Z, Chen H, Lin Y, et al. Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non‐Muscle‐Invasive Bladder Cancer. Cancer Science. 2026;117(3):787-796. doi:10.1111/cas.70311
BibTeX
@article{Xue2026,
author = {Xue, Zihan and Qie, Yunkai and Shen, Chong and Wu, Zhouliang and Chen, Houyuan and Lin, Yuda and Li, Rongjiang and Huang, Shiwang and Hu, Hailong},
title = {Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non‐Muscle‐Invasive Bladder Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {3},
pages = {787--796},
doi = {10.1111/cas.70311}
}
EUVIMED